Amelioration of metabolic and behavioral defects through base editing in the PahR408W phenylketonuria mouse model
Molecular Therapy · 2025
DOI: 10.1016/j.ymthe.2024.11.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2025. Verfasst von Shuming Yin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guang…. Hauptthemen laut MEDLINE: Phenylketonurias, Disease Models, Animal, Phenylalanine Hydroxylase, Gene Editing. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China, Science and Technology Planning Project of Guangdong Province.
Abstract (Originalsprache)
Phenylketonuria (PKU) is a liver metabolic disorder mainly caused by a deficiency of the hepatic phenylalanine hydroxylase (PAH) enzyme activity, often leading to severe brain function impairment in patients if untreated or if treatment is delayed. In this study, we utilized dual-AAV8 vectors to deliver a near PAM-less adenine base editor variant, known as ABE8e-SpRY, to treat the PahR408W PKU mouse model carrying a frequent R408W mutation in the Pah gene. Our findings revealed that a single intravenous injection in adult mice and a single intraperitoneal injection in neonatal mice resulted in 19.1%-34.6% A-to-G editing efficiency at the pathogenic mutation site with minimal bystander edits. Furthermore, the dual-AAV8-treated mice exhibited reduced blood Phe levels to below the therapeutic threshold of 360 μmol L-1 and restored weight and fur color to normal levels. Importantly, the brain function of the mice was restored after the treatment, particularly when administered during the neonatal stage, as levels of monoamine neurotransmitters and metabolites in the brain returned to normal and near-normal levels. Our study demonstrated that ABE8e-SpRY-based base editing could effectively correct the point mutation in the PahR408W PKU mouse model, indicating potential clinical applications for PKU and other genetic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong 510100, China; Shanghai Frontiers Science Center of Ge…
- School of Life Sciences, East China Normal University, Shanghai 200241, China.
- Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, Shanghai 200241, China; School of Life Sciences…
- BRL Medicine, Inc., Shanghai 200241, China.
- Department of Pediatric Endocrinology and Genetics Metabolism, Shanghai Institute for Pediatric Research, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
- Department of Pediatric Endocrinology and Genetics Metabolism, Shanghai Institute for Pediatric Research, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China. Electroni…
Förderung
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Science and Technology Planning Project of Guangdong Province
- National Key Research and Development Program of China
- East China Normal University
- Guangzhou Municipal Science and Technology Project
Zitieren
APA
Yin, S., Gao, L., Sun, X., Zhang, M., Gao, H., Chen, X., Zhang, D., Ming, X., Yang, L., Hu, Y., Chen, X., Liu, M., Zhan, X., Guan, Y., Wang, L., Han, L., Zhu, P., & Li, D. (2025). Amelioration of metabolic and behavioral defects through base editing in the PahR408W phenylketonuria mouse model. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.11.032
Vancouver
Yin S, Gao L, Sun X, Zhang M, Gao H, Chen X, et al. Amelioration of metabolic and behavioral defects through base editing in the PahR408W phenylketonuria mouse model. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2024.11.032
BibTeX
@article{Yin2025,
author = {Yin, Shuming and Gao, Liangcai and Sun, Xiaoyue and Zhang, Mei and Gao, Hongyi and Chen, Xiaoqing and Zhang, Dan and Ming, Xinyu and Yang, Lei and Hu, Yaqiang and Chen, Xi and Liu, Meizhen and Zhan, Xia and Guan, Yuting and Wang, Liren and Han, Lianshu and Zhu, Ping and Li, Dali},
title = {Amelioration of metabolic and behavioral defects through base editing in the PahR408W phenylketonuria mouse model},
journal = {Molecular Therapy},
year = {2025},
doi = {10.1016/j.ymthe.2024.11.032}
}
EUVIMED